MaxCyte
MXCT
About: MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Employees: 114
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3% more funds holding
Funds holding: 115 [Q1] → 118 (+3) [Q2]
1.15% less ownership
Funds ownership: 68.17% [Q1] → 67.01% (-1.15%) [Q2]
21% less capital invested
Capital invested by funds: $198M [Q1] → $156M (-$41.9M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Stephens & Co.
Helfey Hannah
|
$6
|
Overweight
Assumed
|
22 Jul 2025 |
Financial journalist opinion
